Abstracts tagged "ACR"

Abstract Number: 1556 • 2017 ACR/ARHP Annual Meeting
Efficacy of Biologics and New Anti-Inflammatory Agents Used in the Treatment of Active Psoriatic Arthritis: Systematic Literature Review and Network Meta-Analysis of the Evidence.
Mahdi Gharaibeh¹, Yingxin Xu², Joseph Lee³, Madhura Chitnis² and David Collier⁴, ¹Amgen Inc., Thousand Oaks, CA, ²Evidera, Bethesda, MD, ³videra, Bethesda, MD, ⁴Amgen, Inc, Terni, Italy
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Biologics are usually the first-line FDA-approved disease-modifying anti-rheumatic drug (DMARD) treatment; however, no published…
Abstract Number: 2280 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova¹, Ksenia Isaeva¹, Olga Lomakina¹, Margarita Soloshenko¹ and Anna Karaseva¹, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The range of biological drugs currently used in JIA therapy includes not only anti-TNF but also other varieties. However, despite the high effectiveness and…
Abstract Number: 2969 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: 52-Week Results from a Phase 3 Study
Mark C. Genovese¹, Bernard Combe², Joel Kremer³, David Adams⁴, Chin Lee⁴, Lisa Kerr⁴ and Peter Nash⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³St. Peter's Hospital, Albany, NY, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. In patients with active psoriatic arthritis (PsA) who had an inadequate response…
Abstract Number: 1686 • 2016 ACR/ARHP Annual Meeting
Association of Early Skin Improvement with ACR Responses Among Biologic DMARD-Naive Psoriatic Arthritic Patients Treated with Ixekizumab
Diamant Thaci¹, Akimichi Morita², Julie Birt³, Chen-Yen Lin³, Catherine L. Shuler³ and Alice B. Gottlieb⁴, ¹Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ²Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Tufts University School of Medicine, Boston, MA
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. In a phase 3 study, IXE was superior to placebo (PBO) in achieving…
Abstract Number: 2202 • 2016 ACR/ARHP Annual Meeting
Comparison of New and Old American College of Rheumatology Classification Criterion for Diagnosis of Fibromyalgia
Kenrin Shi¹, Kenji Miki² and Masao Yukioka³, ¹Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ²Center for Pain Management, Osaka University Hospital, Suita, Japan, ³Orthopaedic Surgery, Yukioka hospital, Osaka, Japan
Background/Purpose: Fibromyalgia (FM) is a chronic disease characterized by severe, long lasting pain that spreads widely in almost whole body. The cause of the disease…
Abstract Number: 2661 • 2016 ACR/ARHP Annual Meeting
Performance of the Proposed ACR-EULAR Criteria for Sjogren’s Syndrome in a Prospective Multidisciplinary Diagnostic Cohort from Daily Clinical Practice
Jolien F. van Nimwegen¹, Martha S. van Ginkel¹, Suzanne Arends¹, Gwenny M. Verstappen¹, Erlin A. Haacke^1,2, Bert van der Vegt³, Nicole Sillevis Smitt-Kamminga⁴, Fred K.L. Spijkervet⁵, Frans G.M. Kroese¹, Arjan Vissink⁶ and Hendrika Bootsma¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Pathology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Opthalmology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Sjögren’s syndrome (SS) is a systemic auto-immune disease with a heterogeneous clinical presentation. Recently, ACR-EULAR criteria were proposed for classification of SS, which combine…
Abstract Number: 1487 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis in Patients Who Have Failed to Disease-Modifying Antirheumatic Drugs: Long Term Results of the Brazilian Cohort
Wiliam Chahade¹, Cristiano Zerbini², Sebastiao Radominski³, Morton Scheinberg⁴, Walber P. Vieira⁵ and Ana Paula Garcia Lucco⁶, ¹Director-Rheumatology, Hospital Servidor Estadual, Sao Paulo, Brazil, ²Centro Paulista de Investigação Clinica, São Paulo, Brazil, ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Clinical Research, Hospital Abreu Sodre-AACD, Sao Paulo, Brazil, ⁵Hospital Geral de Fortaleza, Fortaleza, Brazil, ⁶Produtos Roche Químicos e Farmacêuticos SA, São Paulo, Brazil
Background/Purpose: Tocilizumab is a humanized monoclonal antibody that binds to IL-6 receptor, blocking its effects. The efficacy and safety of tocilizumab in rheumatoid arthritis (RA)…
Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting
Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis
Vidhu Anand¹, Sachit Anand², Sushil Garg³, Maria A. Lopez-Olivo⁴ and Jasvinder A. Singh⁵, ¹University of Minnesota, Minneapolis, MN, ²All India Institute of Medical Sciences, New Delhi, India, ³The University of Minnesota, Minneapolis, MN, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
Abstract Number: 1496 • 2014 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
Chi-Yuan Wu¹, Denise Jin¹, Alex Godwood², David Close³, Lorin Roskos⁴ and Bing Wang¹, ¹Clinical Pharmacology and DMPK, Medimmune, Mountain View, CA, ²Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, ³Clinical Development, MedImmune Ltd, Cambridge, United Kingdom, ⁴One MedImmune Way, Medimmune, Gaithersburg, MD
Background/Purpose: Mavrilimumab is a recombinant human monoclonal antibody which neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF) activity by selectively binding to the alpha subunit of its…
Abstract Number: 2524 • 2013 ACR/ARHP Annual Meeting
Application of The 2012 Systemic Lupus International Collaborating Clinics Classification Criteria On a Regional Swedish Systemic Lupus Erythematosus Register
Anna Ighe¹, Örjan Dahlström², Thomas Skogh¹ and Christopher Sjöwall¹, ¹Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ²Department of behavioural sciences and learning, Linneaus Centre HEAD, Swedish Institute for Disability Research, Linköping, Sweden
Background/Purpose: In addition to the 1982 American College of Rheumatology criteria (ACR-82) for scientific classification of systemic lupus erythematosus (SLE), many clinicians find the 'Fries…
Abstract Number: 2323 • 2013 ACR/ARHP Annual Meeting
Comprehensive Disease Remission Achieved By Certolizumab Pegol Treatment, and Factors Associated With Certolizumab Pegol Comprehensive Disease Remission, In Rheumatoid Arthritis Patients With Predominantly High Disease Activity
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Katsumi Eguchi⁶, Akira Watanabe⁷, Hideki Origasa⁸, Tadao Okamoto⁹, Yumiko Wada⁹, Toshiharu Shoji⁹, Nobuyuki Miyasaka¹⁰ and Takao Koike¹¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Keio University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Nagoya, Japan, ⁶Sasebo City General Hospital, Sasebo, Japan, ⁷Tohoku University, Sendai, Japan, ⁸Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, ⁹UCB Pharma, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹NTT Sapporo Medical Center, Sapporo, Japan
Background/Purpose: The therapeutic goals of treating rheumatoid arthritis (RA) are clinical, structural and functional remissions.1,2 Simultaneously achieving all three has been referred to as comprehensive…
Abstract Number: 1340 • 2013 ACR/ARHP Annual Meeting
Functional Disability and Quality Of Life Are More Likely Improved In Patients With Rheumatoid Arthritis Who Achieved The New ACR/EULAR Remission Criteria Compared To DAS28 Remission In Daily Practice
Yoko Shimizu¹, Ayako Nakajima², Eisuke Inoue³, Eiichi Tanaka⁴, Akiko Kobayashi³, Yohei Seto³, Shigeki Momohara³, Atsuo Taniguchi³ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The new ACR/EULAR remission criteria were proposed to predict favorable outcome in patients with rheumatoid arthritis (RA). To evaluate the functional disability and quality…
Abstract Number: 861 • 2013 ACR/ARHP Annual Meeting
Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey
Max I. Hamburger¹, Michael H. Pillinger², Robert Sederman³ and Gary Fernandez⁴, ¹Rheumatology Associates, Melville, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³C1 Consulting, LLC, Summit, NJ, ⁴Market Research, Savient Pharmaceuticals, Bridgewater, NJ
Background/Purpose: In Oct 2012, the ACR published guidelines for the management of gout. These guidelines recommend pharmacologic treatment that results in a sufficient lowering of…
Abstract Number: 434 • 2013 ACR/ARHP Annual Meeting
Results Of 64 Weeks Of Treatment With An Anti-IL-17 Antibody, Ixekizumab, In Patients With Rheumatoid Arthritis In a Phase 2 Study
Mark C. Genovese¹, Hilde Carlier², Janelle Erickson², Daniel Braun² and Subhashis Banerjee², ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²Eli Lilly & Company, Indianapolis, IN
Background/Purpose: Ixekizumab, a monoclonal antibody that neutralizes IL-17A with high affinity and specificity, has been evaluated in patients (pts) with moderate to severe rheumatoid arthritis…
Abstract Number: L3 • 2012 ACR/ARHP Annual Meeting
Classification Criteria for Systemic Sclerosis: Preliminary Results
Janet E. Pope¹, Dinesh Khanna², Jaap Fransen³, Sindhu R. Johnson⁴, Murray Baron⁵, Alan G. Tyndall⁶, Marco Matucci-Cerinic⁷, Raymond P. Naden⁸, Frank H.J. van den Hoogen⁹ and ACR/EULAR Classification Criteria for Systemic Sclerosis¹⁰, ¹Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, ⁵Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ⁶Rheumatology, University of Basel, Basel, Switzerland, ⁷Department of Biomedicine & Division of Rheumatology AOUC, University of Florence, Florence, Italy, ⁸Auckland City Hospital, Auckland, New Zealand, Austria, ⁹Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ¹⁰Janet Pope, London, ON, Canada
Background/Purpose: The existing 1980 classification criteria for systemic sclerosis (SSc) are suboptimal for patients with early SSc and some patients with limited cutaneous SSc (lcSSc)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].